By Fineline Cube 
Gilead Sciences (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorisation for the Trop‑2 antibody‑drug conjugate Trodelvy (sacituzumab govitecan‑hziy) in combination with Merck & Co., Inc. (MSD; NYSE: MRK)‘s PD‑1 antibody Keytruda (pembrolizumab). The approval covers adult patients with unresectable, locally advanced or metastatic triple‑negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and whose tumours express PD‑L1 with a combined positive score (CPS) ≥10.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | European Commission (EC) |
| Approval Date | 24 Aug 2026 |
| Product | Trodelvy (sacituzumab govitecan‑hziy) + Keytruda (pembrolizumab) |
| Indication | First‑line unresectable, locally advanced or metastatic PD‑L1‑positive (CPS ≥10) TNBC |
| Supporting Data | Phase 3 ASCENT‑04/KEYNOTE‑D19 study |
| Significance | Establishes an ADC + immunotherapy backbone as a new first‑line TNBC standard in Europe |
Drug Profile & Mechanism of Action
- Trodelvy: Trop‑2‑directed antibody‑drug conjugate (ADC) delivering a topoisomerase I inhibitor payload to Trop‑2‑expressing tumour cells
- Keytruda: Anti‑PD‑1 monoclonal antibody that restores T‑cell‑mediated anti‑tumour immunity
- Combination Rationale: ADC‑mediated tumour killing combined with checkpoint blockade to deepen and prolong responses in first‑line metastatic TNBC
- Target Population: PD‑L1‑positive (CPS ≥10) patients with no prior systemic therapy for metastatic disease
Clinical Evidence – ASCENT‑04/KEYNOTE‑D19 (Phase 3)
| Endpoint | Outcome (Trodelvy + Keytruda vs. SoC Chemotherapy + Keytruda) |
|---|---|
| Progression‑Free Survival (PFS) | Highly statistically significant and clinically meaningful improvement |
| Risk of Disease Progression or Death | 35% reduction in PD‑L1‑positive metastatic TNBC |
| Setting | First‑line metastatic TNBC |
The pivotal Phase 3 ASCENT‑04/KEYNOTE‑D19 study demonstrated that Trodelvy plus Keytruda delivered a highly statistically significant and clinically meaningful progression‑free survival benefit over the prior first‑line standard of care — chemotherapy combined with Keytruda — reinforcing the ADC + immunotherapy approach as a differentiated treatment paradigm in TNBC.
Market Impact & Outlook
- Standard of Care Shift: The approval establishes an ADC‑based combination as a new first‑line option in Europe, potentially displacing chemotherapy + Keytruda regimens in PD‑L1‑positive metastatic TNBC.
- Strategic Alliance: The decision underscores the commercial value of the Gilead–Merck (MSD) collaboration, pairing Gilead’s ADC platform with the world’s leading PD‑1 franchise.
- Commercial Upside: TNBC accounts for a meaningful share of breast cancers with historically limited durable treatment options; a first‑line combination label broadens Trodelvy’s addressable market in Europe.
- Catalyst Watch: Label expansion and reimbursement uptake across EU member states, alongside ongoing ASCENT programme readouts, will be key near‑term drivers for GILD’s oncology franchise.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory adoption, clinical uptake, and commercial expectations for Trodelvy in combination with Keytruda. Actual results may differ due to risks including reimbursement decisions, competitive dynamics, and further regulatory actions.-Fineline Info & Tech